On Friday, Regulus Therapeutics Inc (NASDAQ: RGLS) opened higher 3.49% from the last session, before settling in for the closing price of $1.72. Price fluctuations for RGLS have ranged from $0.83 to $2.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -10.71% over the past five years. Company’s average yearly earnings per share was noted -42.89% at the time writing. With a float of $53.18 million, this company’s outstanding shares have now reached $65.50 million.
Let’s look at the performance matrix of the company that is accounted for 34 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Regulus Therapeutics Inc (RGLS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Regulus Therapeutics Inc is 19.71%, while institutional ownership is 67.87%. The most recent insider transaction that took place on Jan 30 ’25, was worth 54,260. In this transaction Chief Executive Officer of this company bought 50,000 shares at a rate of $1.09, taking the stock ownership to the 260,808 shares. Before that another transaction happened on Jan 30 ’25, when Company’s Director bought 19,610 for $1.06, making the entire transaction worth $20,787. This insider now owns 22,169 shares in total.
Regulus Therapeutics Inc (RGLS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -42.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 40.21% growth over the previous five years of trading.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
Check out the current performance indicators for Regulus Therapeutics Inc (RGLS). In the past quarter, the stock posted a quick ratio of 10.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
Regulus Therapeutics Inc (NASDAQ: RGLS) saw its 5-day average volume 0.85 million, a negative change from its year-to-date volume of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 42.38%. Additionally, its Average True Range was 0.19.
During the past 100 days, Regulus Therapeutics Inc’s (RGLS) raw stochastic average was set at 77.87%, which indicates a significant increase from 65.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 122.08% in the past 14 days, which was higher than the 88.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4009, while its 200-day Moving Average is $1.5241. Nevertheless, the first resistance level for the watch stands at $1.8667 in the near term. At $1.9533, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0717. If the price goes on to break the first support level at $1.6617, it is likely to go to the next support level at $1.5433. Assuming the price breaks the second support level, the third support level stands at $1.4567.
Regulus Therapeutics Inc (NASDAQ: RGLS) Key Stats
There are currently 66,243K shares outstanding in the company with a market cap of 117.91 million. Presently, the company’s annual sales total 0 K according to its annual income of -46,360 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -12,790 K.
